Published in Clin Diabetes Endocrinol on May 11, 2016
Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes. Curr Geriatr Rep (2017) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Severe hypoglycemia and risks of vascular events and death. N Engl J Med (2010) 8.54
Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia (2009) 6.55
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet (2014) 4.01
Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care (2013) 3.89
Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med (2015) 3.20
Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care (2003) 3.08
A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care (2006) 2.40
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care (2002) 1.91
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med (2010) 1.70
Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther (2002) 1.64
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J (2013) 1.62
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med (2004) 1.34
Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care (2007) 1.32
Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther (2012) 1.30
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care (2003) 1.30
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol (2011) 1.21
Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab (2013) 1.13
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care (2015) 1.12
The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism (2002) 1.06
Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des (2001) 1.05
Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care (2003) 1.03
Standardised MedDRA queries: their role in signal detection. Drug Saf (2007) 1.02
Amylin concentrations and glucose control. Lancet (1992) 1.00
Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res (2011) 0.98
Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc Health Risk Manag (2008) 0.94
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. Am Heart J (2015) 0.93
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol (2014) 0.87
Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes (1991) 0.87
Anorexia following the intrahypothalamic administration of amylin. Brain Res (1991) 0.87
Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and β-cell function. Am J Physiol Endocrinol Metab (2014) 0.86
Hypoglycemia-induced angina pectoris in a patient with diabetes mellitus. Ann Intern Med (1994) 0.86
Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care (2009) 0.85
Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. Curr Med Res Opin (2008) 0.83
Cardiovascular safety profile of currently available diabetic drugs. Ochsner J (2014) 0.81
Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes. Diabetes Obes Metab (2015) 0.75